Profile data is unavailable for this security.
About the company
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
- Revenue in USD (TTM)11.72bn
- Net income in USD3.68bn
- Incorporated1989
- Employees6.10k
- LocationVertex Pharmaceuticals Inc50 Northern AvenueBOSTON 02210United StatesUSA
- Phone+1 (617) 341-6393
- Websitehttps://www.vrtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 14.34bn | 4.55bn | 79.81bn | 15.41k | 17.99 | 2.55 | 15.67 | 5.56 | 41.96 | 41.55 | 131.98 | 295.71 | 0.3663 | 0.6934 | 2.40 | 930,752.80 | 11.62 | 16.41 | 13.00 | 18.57 | 86.56 | 87.14 | 31.72 | 36.23 | 3.56 | -- | 0.0797 | 1.50 | 0.9921 | 11.04 | 3.10 | 5.31 | 14.58 | -- |
| Vertex Pharmaceuticals Inc | 11.72bn | 3.68bn | 117.59bn | 6.10k | 32.57 | 6.80 | 30.34 | 10.03 | 14.23 | 14.23 | 45.38 | 68.20 | 0.4978 | 1.19 | 6.34 | 1,921,853.00 | 15.60 | 14.06 | 19.02 | 16.67 | 86.28 | 87.35 | 31.35 | 26.28 | 2.00 | -- | 0.00 | 0.00 | 11.66 | 21.50 | -114.80 | -- | 45.11 | -- |
| Bristol-Myers Squibb Co | 48.19bn | 7.05bn | 123.90bn | 34.10k | 17.60 | -- | 11.35 | 2.57 | 3.46 | 3.46 | 23.63 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 72.62 | 76.32 | 14.64 | 8.34 | -- | 16.84 | -- | -- | -0.2195 | 2.54 | 178.83 | -- | -- | 0.658 |
| Pfizer Inc | 62.58bn | 7.75bn | 156.98bn | 81.00k | 20.37 | -- | 11.28 | 2.51 | 1.36 | 1.36 | 10.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 75.81 | 69.03 | 12.44 | 19.52 | -- | 9.38 | -- | -- | -1.65 | 8.48 | -3.42 | 3.16 | -- | 2.50 |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Sep 2025 | 25.91m | 10.21% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 21.55m | 8.50% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2025 | 16.55m | 6.52% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 14.47m | 5.70% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 11.61m | 4.57% |
| Geode Capital Management LLCas of 30 Sep 2025 | 5.97m | 2.35% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2025 | 4.69m | 1.85% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 4.62m | 1.82% |
| AllianceBernstein LPas of 30 Sep 2025 | 4.52m | 1.78% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2025 | 4.31m | 1.70% |
